Christopher G. Willett
Department of Radiation Oncology
Massachusetts General Hospital
55 Fruit Street
Boston
USA
Name/email consistency: high
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T., Chung, D.C., Sahani, D.V., Kalva, S.P., Kozin, S.V., Mino, M., Cohen, K.S., Scadden, D.T., Hartford, A.C., Fischman, A.J., Clark, J.W., Ryan, D.P., Zhu, A.X., Blaszkowsky, L.S., Chen, H.X., Shellito, P.C., Lauwers, G.Y., Jain, R.K. Nat. Med. (2004)
- Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Willett, C.G., Safran, H., Abrams, R.A., Regine, W.F., Rich, T.A. Int. J. Radiat. Oncol. Biol. Phys. (2003)
- Update on combined-modality treatment options for pancreatic cancer. Willett, C.G., Clark, J.W. Oncology (Williston Park, N.Y.) (2003)
- Intraoperative radiation therapy. Willett, C.G. Int. J. Clin. Oncol. (2001)